CNS Trial Imaging:
The presentation and progression of CNS disease is complex. But CNS trial imaging doesn’t have to be.
Calyx is a trusted name in medical imaging, with over 25 years of experience supporting more than 2,600 clinical trials. Although we are widely known for our oncology expertise, we also have extensive experience in neuroimaging, including neuro-oncologic, neuro-degenerative, and neuro-psychiatric indications.
We have provided essential imaging services for nearly 200 clinical trials with CNS imaging, many of which have resulted in approved medical treatments.
These are the central nervous system (CNS) studies supported:
- CNS/Neurology Studies | 176
- Multiple sclerosis studies | 37
- Stroke Studies | 37
- Neuro-oncology | 33
- Alzheimer’s disease studies | 21
- Parkinson’s studies | 7
- Seizure studies | 5
- Neuropathy studies | 3
- Acromegaly/Pituitary Adenoma | 3
- Sickle Cell studies | 3
- Dementia studies | 2
- Brain Injury studies | 2
- Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) | 2
- Spinal Cord Injury studies | 1
- Migraines | 1
- Schizophrenia | 1
- Adrenoleukodystrophy (ALD) | 1
- Multiple System atrophy (MSA) | 1
Calyx Neuro-imaging Expertise
Calyx Medical Imaging is a leading imaging core lab with the experience and ability to provide a wide range of services involving neuroimaging in clinical trials. With a firm understanding of the unique and custom requirements of neuro-imaging trials, Calyx has the flexibility, creativity, and bandwidth to effectively manage and support these clinical trials.
The resources below capture some of the expertise Calyx brings to the table in neurodegenerative, neuro-oncology, and neuro-psychiatric disorder imaging.
Neuro-degenerative Disorder Resources
Neuro-oncology Disorder Resources
Neuro-psychiatric Disorder Resources
Meet the Experts
By working with Calyx, you have access to some of the industry’s most renowned imaging experts. Our in-house medical imaging experts, including MDs, PhDs, imaging technologists, imaging physicists, and a dedicated Exploratory Imaging group are equipped and well-positioned to help you gain the information needed from new and novel imaging methods.
Calyx’s comprehensive suite of neuro-imaging services includes:
- Protocol Consulting
- Site Feasibility
- Design of image acquisition protocols
- Preparation of Independent Review Charters (IRC)
- Site standardization, training, and management
- Reviewer selection, training, and monitoring)
- Independent review and eligibility/safety review
- Regulatory support
Partnering for CNS Trial Success
Calyx is committed to delivering the most reliable and effective medical imaging to drive our customers’ success. A key component of our strategy is to partner with best-in-class providers of AI-based solutions to deliver quantitative endpoint assessments, a robust independent review framework, and innovative
Our groundbreaking partnership with Qynapse enables our clients to more confidently assess the full potential of treatments in development for Multiple Sclerosis, Parkinson’s, Alzheimer’s, and Huntington’s disease, as well as other neurodegenerative disorders.
And our partnership with Neosoma delivers novel, improved AI-based neuro-oncology imaging assessment to clinical trial sponsors developing new treatments for gliobastoma and other life-threatening neuro-oncological diseases.
Calyx’s Medical Imaging team leverages our established operational footprint to implement an imaging strategy that acquires complex yet optimized CNS images from investigative sites around the world.
With local support in India, China, North America, and Europe, you can have confidence that the imaging components of your CNS trial will run smoothly and deliver high quality data you can rely on. Every time.
Discover Our Therapeutic Expertise
Calyx’s expertise spans across all phases of clinical development and therapeutic areas. In addition to CNS, we have significant experience and proven capabilities in providing medical imaging services to support the clinical development of new treatments in oncology, musculoskeletal, and many other therapeutic areas.